NCT05216614

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the efficacy of oral fluvoxamine in olfactory improvement following Covid-19- associated parosmia. This is a randomized, double-blinded, placebo-controlled trial.

Detailed description

The drug will be given over a 14 weeks with six weeks titrating up, six weeks maintaining highest dose, and up to two weeks tapering down. Assessments will be collected following week 12 to measure change in olfactory function from baseline between the two study groups.

Conditions

• COVID-19
• Olfactory Disorder
• Parosmia

Interventions

Type	Name	Description
DRUG	Fluvoxamine	Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
DRUG	Placebo	lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind

Timeline

• Start date: 2021-12-14
• Primary completion: 2022-02-22
• Completion: 2022-02-22
• First posted: 2022-01-31
• Last updated: 2022-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study